Sequencing and Individualizing Care with FcRn Targeting Therapies in Myasthenia Gravis

Understanding where immune dysfunction occurs in MG provides the foundation for selecting increasingly targeted therapies. The panel connects disease biology with upstream and downstream treatment strategies.

Controlling MG symptoms and modifying its underlying immunology are related but distinct treatment goals. The panel explores how targeted therapies are changing the way clinicians think about remission and disease modification.